Table 4 (*Continued*)

Hematology data (1-year toxicity study)

Sex	Treatment Dammar resin	No. of animal	MCV (fl)	MCH (pg)	MCHC (%)
Male					
	Control	10	50.23 ± 0.71	16.63 ± 0.35	33.11 ± 0.61
	0.03%	10	49.71 ± 1.30	16.16 ± 0.20*	32.52 ± 0.63*
	0.125%	10	49.96 ± 0.56	16.19 ± 0.19*	32.41 ± 0.29*
	0.5%	10	50.42 ± 0.57	16.32 ± 0.27*	32.38 ± 0.53*
	2%	10	51.41 ± 0.83*	16.20 ± 0.17*	31.51 ± 0.46*
Female					
	Control	10	55.64 ± 1.41	18.12 ± 0.16	32.59 ± 0.94
	0.03%	10	56.62 ± 1.18	18.09 ± 0.18	31.97 ± 0.55
	0.125%	10	56.83 ± 1.28	17.86 ± 0.17*	31.43 ± 0.66*
	0.5%	10	57.40 ± 1.51*	17.64 ± 0.59*	30.75 ± 1.48*
	2%	10	58.91 ± 1.71*	17.18 ± 0.28*	29.17 ± 0.66*

* Significantly different from control group.

Table 5

Serum chemistry data (1-year toxicity study)

Sex	Treatment Dammar resin	No. of animal	AST (IU/l)	ALT (IU/l)	ALP (IU/l)	γ-GTP (IU/l)	T-BiL (mg/dl)
Male							
	Control	10	176.80 ± 40.94	107.40 ± 26.31	376.20 ± 29.53	3.10 ± 1.85	0.10 ± 0.00
	0.03%	10	177.00 ± 50.47	110.30 ± 22.72	369.90 ± 49.75	3.00 ± 1.05	0.10 ± 0.00
	0.125%	10	148.50 ± 21.37	89.50 ± 11.44	332.90 ± 47.04	3.70 ± 2.16	0.10 ± 0.00
	0.5%	10	117.70 ± 27.68*	62.50 ± 12.74*	290.90 ± 38.99*	2.50 ± 1.27	0.10 ± 0.00
	2%	10	66.00 ± 7.32*	49.00 ± 4.74*	284.40 ± 14.29*	2.20 ± 0.63	0.10 ± 0.00
Female							
	Control	10	125.10 ± 35.71	52.50 ± 11.94	234.10 ± 56.30	1.10 ± 0.32	0.10 ± 0.00
	0.03%	10	103.30 ± 19.40	47.80 ± 10.22	205.00 ± 46.10	1.20 ± 0.63	0.10 ± 0.00
	0.125%	10	107.70 ± 23.37	45.50 ± 4.88	189.40 ± 32.07	1.40 ± 0.52	0.10 ± 0.00
	0.5%	10	87.10 ± 16.00*	40.70 ± 4.85*	148.00 ± 25.58*	2.50 ± 0.53*	0.10 ± 0.00
	2%	10	68.60 ± 14.77*	43.20 ± 4.59*	183.60 ± 38.20*	15.60 ± 3.92*	0.10 ± 0.00

* Significantly different from control group.

Table 5 (*Continued*)

Serum chemistry data (1-year toxicity study)

Sex	Treatment Dammar resin	No. of animal	TP (g/dl)	ALB (g/dl)	A/G	TG (mg/dl)	T-Cho (mg/dl)
Male							
	Control	10	6.75 ± 0.24	4.52 ± 0.13	2.02 ± 0.13	92.10 ± 17.65	81.70 ± 7.20
	0.03%	10	6.73 ± 0.16	4.52 ± 0.08	2.04 ± 0.10	91.20 ± 29.07	86.30 ± 7.48
	0.125%	10	6.63 ± 0.18	4.45 ± 0.10	2.04 ± 0.14	69.60 ± 17.88	84.10 ± 9.12
	0.5%	10	6.82 ± 0.19	4.51 ± 0.10	1.95 ± 0.14	61.60 ± 19.79*	83.10 ± 8.09
	2%	10	6.88 ± 0.20	4.70 ± 0.21	2.15 ± 0.19	61.50 ± 14.80*	94.00 ± 9.65*
Female							
	Control	10	6.91 ± 0.60	5.23 ± 0.50	3.16 ± 0.44	84.50 ± 33.22	106.80 ± 16.89
	0.03%	10	7.18 ± 0.35	5.40 ± 0.23	3.06 ± 0.34	119.50 ± 45.25	110.90 ± 12.40
	0.125%	10	7.39 ± 0.38*	5.54 ± 0.32	3.00 ± 0.12	131.00 ± 54.32	119.30 ± 19.07
	0.5%	10	7.71 ± 0.29*	5.72 ± 0.18*	2.90 ± 0.22	138.90 ± 34.47*	139.50 ± 16.53*
	2%	10	7.37 ± 0.29*	5.31 ± 0.21	2.59 ± 0.14*	97.20 ± 49.64	162.00 ± 21.98*

* Significantly different from control group.

Table 5 (*Continued*)

Serum chemistry data (1-year toxicity study)

Sex	Treatment Dammar resin	No. of animal	Creatine (mg/dl)	BUN (mg/dl)	Na (mEq/l)	K (mEq/l)	Cl (mEq/l)
Male							
	Control	10	0.31 ± 0.04	20.30 ± 4.50	144.70 ± 1.25	4.54 ± 0.32	103.50 ± 1.27
	0.03%	10	0.32 ± 0.05	19.90 ± 3.07	144.50 ± 1.65	4.57 ± 0.22	103.50 ± 1.96
	0.125%	10	0.30 ± 0.05	19.40 ± 2.84	144.00 ± 1.76	4.57 ± 0.42	102.40 ± 1.84
	0.5%	10	0.27 ± 0.03	17.50 ± 2.46	144.70 ± 1.16	4.64 ± 0.35	101.30 ± 1.83*
	2%	10	0.28 ± 0.05	22.30 ± 4.74	145.20 ± 0.79	4.27 ± 0.39	102.10 ± 1.10
Female							
	Control	10	0.28 ± 0.05	26.30 ± 4.42	144.20 ± 1.69	4.48 ± 0.34	100.90 ± 1.29
	0.03%	10	0.30 ± 0.04	20.80 ± 4.08*	144.60 ± 2.01	4.43 ± 0.53	101.60 ± 1.07
	0.125%	10	0.29 ± 0.04	22.30 ± 3.53	144.30 ± 1.64	4.26 ± 0.24	101.60 ± 1.51
	0.5%	10	0.28 ± 0.03	23.70 ± 4.37	144.90 ± 1.29	4.22 ± 0.38	100.30 ± 1.42
	2%	10	0.26 ± 0.03	26.30 ± 5.79	143.80 ± 1.55	4.48 ± 0.38	100.60 ± 1.07

* Significantly different from control group.

Table 5 (*Continued*)

Serum chemistry data (1-year toxicity study)

Sex	Treatment Dammar resin	No. of animal	Ca (mg/dl)	P (mg/dl)
Male				
	Control	10	10.31 ± 0.20	5.08 ± 0.75
	0.03%	10	10.39 ± 0.26	5.41 ± 0.56
	0.125%	10	10.21 ± 0.09	5.27 ± 0.61
	0.5%	10	10.35 ± 0.25	5.46 ± 0.45
	2%	10	10.68 ± 0.15*	5.33 ± 0.47
Female				
	Control	10	10.34 ± 0.49	4.44 ± 0.83
	0.03%	10	10.47 ± 0.36	3.99 ± 1.34
	0.125%	10	10.53 ± 0.53	4.14 ± 0.71
	0.5%	10	10.86 ± 0.32	4.56 ± 0.86
	2%	10	10.40 ± 0.38	5.15 ± 0.76

* Significantly different from control group.

Table 6

Urinalysis data (1-year toxicity study)

Treatment Dammar resin	No. of animal	Protein					Glucose		Ketone			
		-	+/-	30mg/dl	100mg/dl	≧300mg/dl	-	100mg/dl	-	+/-	1+	2+
Male												
Control	10	0	0	0	6	4	9	0	0	0	7	3
0.03%	10	0	0	0	6	4	10	0	0	0	8	2
0.125%	10	0	0	0	4	6	10	0	0	0	10	0
0.5%	10	0	0	0	1	9	9	0	0	0	9	1
2%	10	0	0	0	0	10*	9	1	0	1	9	0
Female												
Control	10	0	0	2	7	1	10	0	4	6	0	0
0.03%	10	0	0	5	5	0	10	0	3	7	0	0
0.125%	10	0	0	4	4	2	9	0	0	6	4	0
0.5%	10	0	0	0	5	5	10	0	2	6	2	0
2%	10	0	0	3	5	2	10	0	5	5	0	0

* Significantly different from control group.

Table 6 *(Continued)*

Urinalysis data (1-year toxicity study)

Treatment	No. of	Specific gravity				Occult blood					Bilirubin	
Dammar resin	animal	1.015	1.020	1.025	≧1.030	-	+/-	1+	2+	3+	-	1+
Male												
Control	10	0	6	1	3	7	0	0	2	1	7	3
0.03%	10	0	9	1	0	9	1	0	0	0	7	3
0.125%	10	0	7	2	1	9	1	0	0	0	7	3
0.5%	10	1	3	5	1	7	2	0	1	0	7	3
2%	10	0	10	0	0	8	2	0	0	0	8	2
Female												
Control	10	0	9	1	0	10	0	0	0	0	8	2
0.03%	10	0	7	2	1	9	0	1	0	0	8	2
0.125%	10	0	6	3	1	8	0	0	0	2	9	0
0.5%	10	1	7	2	0	10	0	0	0	0	9	1
2%	10	3	7	0	0	9	1	0	0	0	10	0

Table 6 *(Continued)*

Urinalysis data (1-year toxicity study)

Treatment	No. of	pH				Urobilinogen		Nitrite	
Dammar resin	animal	7.0	7.5	8.0	8.5	0.1 E.U./dl	1.0 E.U./dl	-	+
Male									
Control	10	3	0	4	3	6	3	8	1
0.03%	10	1	2	6	1	3	7	9	1
0.125%	10	1	4	1	4	2	8	10	0
0.5%	10	1	4	3	2	7	3	9	0
2%	10	0	0	3	7	8	2	10	0
Female									
Control	10	0	3	2	5	2	8	10	0
0.03%	10	0	2	0	8	6	4	10	0
0.125%	10	0	0	1	9	1	9	9	0
0.5%	10	0	1	0	9	2	8	10	0
2%	10	0	1	1	8	7	3	10	0

Table 7

Organ weights (1-year toxicity study)

Sex	Treatment Dammar resin	No. of animal	Liver		Kidney		Spleen		Thymus	
			Absolute (g)	Relative (%)	Absolute (g)	Relative (g)	Absolute (g)	Relative (%)	Absolute (g)	Relative (%)
Male										
	Control	10	9.33 ± 0.54	2.08 ± 0.17	2.36 ± 0.28	0.53 ± 0.07	0.75 ± 0.04	0.17 ± 0.01	0.048 ± 0.010	0.011 ± 0.002
	0.03%	10	9.92 ± 0.60	2.08 ± 0.09	2.49 ± 0.13	0.52 ± 0.04	0.78 ± 0.06	0.16 ± 0.01	0.050 ± 0.012	0.011 ± 0.002
	0.125%	10	9.82 ± 0.61	2.13 ± 0.06	2.36 ± 0.13	0.51 ± 0.01	0.73 ± 0.04	0.16 ± 0.01	0.049 ± 0.011	0.011 ± 0.003
	0.5%	10	10.40 ± 0.96*	2.25 ± 0.09*	2.46 ± 0.21	0.53 ± 0.03	0.75 ± 0.04	0.16 ± 0.01	0.049 ± 0.009	0.011 ± 0.002
	2%	10	10.68 ± 0.82*	2.66 ± 0.09*	2.43 ± 0.24	0.61 ± 0.06	0.69 ± 0.06*	0.17 ± 0.01	0.047 ± 0.006	0.012 ± 0.002
Female										
	Control	10	4.72 ± 0.36	2.11 ± 0.16	1.48 ± 0.07	0.66 ± 0.05	0.43 ± 0.04	0.19 ± 0.02	0.053 ± 0.010	0.024 ± 0.004
	0.03%	10	5.04 ± 0.26	2.10 ± 0.12	1.46 ± 0.10	0.61 ± 0.04*	0.44 ± 0.04	0.18 ± 0.02	0.055 ± 0.007	0.023 ± 0.003
	0.125%	10	5.01 ± 0.51	2.10 ± 0.16	1.39 ± 0.10	0.58 ± 0.04*	0.42 ± 0.04	0.18 ± 0.01	0.049 ± 0.015	0.020 ± 0.006
	0.5%	10	6.08 ± 0.77*	2.61 ± 0.15*	1.43 ± 0.13	0.61 ± 0.03*	0.42 ± 0.04	0.18 ± 0.01	0.047 ± 0.012	0.020 ± 0.005
	2%	10	6.74 ± 0.49*	3.25 ± 0.21*	1.44 ± 0.06	0.70 ± 0.03	0.37 ± 0.04*	0.18 ± 0.02	0.054 ± 0.008	0.026 ± 0.004

* Significantly different from control group.

Table 7 (*Continued*)

Organ weights (1-year toxicity study)

Sex	Treatment Dammar resin	No. of animal	Heart		Brain		Adrenal		Testis	
			Absolute (g)	Relative (%)	Absolute (g)	Relative (%)	Absolute (g)	Relative (%)	Absolute (g)	Relative (%)
Male										
	Control	10	1.10 ± 0.04	0.25 ± 0.01	2.10 ± 0.05	0.47 ± 0.02	0.043 ± 0.006	0.010 ± 0.001	3.38 ± 0.17	0.75 ± 0.04
	0.03%	10	1.18 ± 0.07*	0.25 ± 0.01	2.15 ± 0.08	0.45 ± 0.02	0.048 ± 0.004	0.010 ± 0.001	3.53 ± 0.46	0.74 ± 0.11
	0.125%	10	1.15 ± 0.07	0.25 ± 0.01	2.04 ± 0.06	0.44 ± 0.03	0.039 ± 0.004	0.008 ± 0.001	3.35 ± 0.36	0.73 ± 0.08
	0.5%	10	1.17 ± 0.08	0.25 ± 0.02	2.09 ± 0.04	0.46 ± 0.03	0.063 ± 0.067	0.014 ± 0.015	3.35 ± 0.25	0.73 ± 0.05
	2%	10	1.09 ± 0.09	0.27 ± 0.01*	2.04 ± 0.07	0.51 ± 0.02*	0.043 ± 0.006	0.011 ± 0.002	3.42 ± 0.18	0.85 ± 0.05*
Female										
	Control	10	0.70 ± 0.04	0.31 ± 0.01	1.88 ± 0.06	0.84 ± 0.04	0.049 ± 0.004	0.022 ± 0.002	---	---
	0.03%	10	0.71 ± 0.04	0.30 ± 0.02	1.86 ± 0.04	0.78 ± 0.03*	0.051 ± 0.007	0.021 ± 0.003	---	---
	0.125%	10	0.69 ± 0.05	0.29 ± 0.01*	1.88 ± 0.04	0.79 ± 0.05	0.054 ± 0.007	0.022 ± 0.003	---	---
	0.5%	10	0.73 ± 0.06	0.31 ± 0.03	1.83 ± 0.09	0.79 ± 0.08	0.049 ± 0.005	0.021 ± 0.003	---	---
	2%	10	0.65 ± 0.21	0.31 ± 0.10	1.66 ± 0.40	0.80 ± 0.21	0.044 ± 0.008	0.021 ± 0.003	---	---

* Significantly different from control group.

Table 8

Histopathological findings in livers (1-year toxicity study)

Sex	Treatment Dammar resin	No. of animal	Bile duct hyperplasia				Inflammatory cell infiltration		Microgranuloma	
			0	1	2	3	-	+	-	+
Male										
	Control	10	0	0	7	3	6	4	7	3
	0.03%	10	0	0	7	3	8	2	9	1
	0.125%	10	0	0	8	2	6	4	8	2
	0.5%	10	0	1	9	0	7	3	10	0
	2%	10	8*	2	0	0	5	5	10	0
Female										
	Control	10	7	3	0	0	7	3	6	4
	0.03%	10	8	2	0	0	6	4	6	4
	0.125%	10	7	2	1	0	8	2	6	4
	0.5%	10	9	1	0	0	8	2	9	1
	2%	10	10	0	0	0	6	4	9	1

0, negative; 1, slight; 2 , moderate; 3, extensive.

* Significantly different from control group.

Table 9

Development of GST-P positive foci in livers of male rats (1-year toxicity study)

Treatment	No. of	No. of GST-P positive foci /cm^2 (no. of rat)			
Dammar resin	animal	Diameter □0.1 mm, <0.2 mm	Diameter □0.2 mm, <0.4 mm	Diameter □ 0.4mm	Total
Control	10	1.6 ± 1.4 (9)	0.4 ± 0.5 (6)	0 (0)	2.1 ± 1.8 (9)
0.03%	10	0.8 ± 0.6 (9)	0.1 ± 0.5 (1)	0 (0)	0.9 ± 0.8 (9)
0.125%	10	1.0 ± 0.9 (8)	0.3 ± 0.4 (4)	0 (0)	1.2 ± 0.9 (9)
0.5%	10	0.9 ± 0.5 (9)	0.4 ± 0.9 (5)	0 (0)	1.4 ± 1.3 (9)
2%	10	1.2 ± 0.8 (9)	0.5 ± 0.3 (9)	0.1 ± 0.2 (2)	1.8 ± 0.9 (10)

Table 10

Expression of GST-P in livers of female rats (1-year toxicity study)

Treatment	No. of	GST-P positive foci classification			
Dammar resin	animal	0	1	2	3
Control	10	3	7	0	0
0.03%	10	0	10	0	0
0.125%	10	0	9	1	0
0.5%	10	0	2	3	5*
2%	10	0	0	0	10*

0, negative; 1, slight; 2 , moderate; 3, extensive

* Number of class-3 liver significantly different from control group.

Table 11

Histopathological findings in kidney (1-year toxicity study)

		Male					Female				
	Dose (%)	0	0.125	0.125	0.5	2	0	0.125	0.5	0.5	2
	No. of rats examined	<10>[a]	<10>	<10>	<10>	<10>	<10>	-	-	-	<10>
Protein cast	+	1	2	6	3	4	0	-	-	-	0
	2+	0	0	0	4	5 *	0	-	-	-	0
	Positive (Total)	1	2	6	7 *	9 *	0	-	-	-	0
Tubular dilatation	+	0	0	0	1	3	0	-	-	-	0
	2+	0	0	0	1	1	0	-	-	-	0
	Positive (Total)	0	0	0	2	4	0	-	-	-	0

-, no examined.

* Significantly different from control group.

Table 12

Histopathological findings in oragans other than liver and kidney (1-year toxicity study)

Organ/Finding	Male					Female				
Dose (%)	0	0.125	0.5	0.5	2	0	0.125	0.5	0.5	2
Spleen	<10>[a]	-	-	-	<10>	<10>	-	-	-	<10>
Pigment deposition	10	-	-	-	10	10	-	-	-	10
Pancreas	<10>	-	-	-	<10>	<10>	-	-	-	<10>
Inflammatory cell infiltration	4	-	-	-	3	4	-	-	-	1
Proliferation, pancreatic duct	0	-	-	-	2	0	-	-	-	0
Vacuolation, acinar cell	0	-	-	-	0	1	-	-	-	2
Prostate	<10>	-	-	-	<10>	-	-	-	-	-
Inflammatory cell infiltration	2	-	-	-	1	-	-	-	-	-
Pituitary	<10>	-	-	-	<10>	<9>	-	-	-	<10>
Cyst	1	-	-	-	0	0	-	-	-	0
Cyst like lesion	0	-	-	-	0	3	-	-	-	2
Thyroid	<10>	-	-	-	<10>	<9>	-	-	-	<10>
Ultimobronchial body	1	-	-	-	0	0	-	-	-	2
C-cell hyperplasia	1	-	-	-	2	0	-	-	-	0

[a] Number of rats examined; -, no examined.

Table 13

Summary of average body weight (g) and number of surviving rats (2-year carcinogenicity study)

Dammar resin	WEEK 0	WEEK 1	WEEK 2	WEEK 3	WEEK 4
Male					
Control	(50) [a] 113 ± 6	(50) 162 ± 9	(50) 196 ± 10	(50) 222 ± 11	(50) 241 ± 12
0.03%	(50) 113 ± 5	(50) 164 ± 9	(50) 199 ± 9	(50) 228 ± 9 *	(50) 246 ± 10 *
0.5%	(50) 113 ± 6	(50) 164 ± 8	(50) 200 ± 9	(50) 228 ± 9 *	(50) 249 ± 9 *
2%	(50) 113 ± 6	(50) 156 ± 9 *	(50) 190 ± 12 *	(50) 217 ± 12 *	(50) 235 ± 13
Female					
Control	(50) 94 ± 4	(50) 118 ± 4	(50) 132 ± 5	(50) 141 ± 6	(50) 146 ± 6
0.03%	(50) 94 ± 5	(50) 118 ± 5	(50) 133 ± 6	(50) 143 ± 5	(50) 149 ± 6
0.5%	(50) 94 ± 4	(50) 118 ± 6	(50) 134 ± 5	(50) 144 ± 7 *	(50) 151 ± 6 *
2%	(50) 94 ± 4	(50) 115 ± 5 *	(50) 131 ± 5 *	(50) 141 ± 5	(50) 146 ± 6

[a] Number of surviving rat

* Significantly different from coresponding control group.

Table 13 *(Continued)*

Summary of average body weight (g) and number of surviving rats (2-year carcinogenicity study)

Dammar resin	WEEK 5		WEEK 6		WEEK 7		WEEK 8		WEEK 9	
Male										
Control	(50)	261 ± 13	(50)	276 ± 14	(50)	288 ± 15	(50)	299 ± 16	(50)	309 ± 16
0.03%	(50)	267 ± 11 *	(50)	284 ± 12 *	(50)	299 ± 13 *	(50)	310 ± 14 *	(50)	321 ± 14 *
0.5%	(50)	270 ± 10 *	(50)	287 ± 11 *	(50)	300 ± 12 *	(50)	313 ± 13 *	(50)	323 ± 13 *
2%	(50)	254 ± 14 *	(50)	269 ± 15 *	(50)	282 ± 16	(50)	292 ± 16 *	(50)	302 ± 18
Female										
Control	(50)	159 ± 7	(50)	165 ± 7	(50)	169 ± 7	(50)	173 ± 7	(50)	177 ± 7
0.03%	(50)	161 ± 7	(50)	168 ± 7	(50)	172 ± 8	(50)	177 ± 7 *	(50)	181 ± 7 *
0.5%	(50)	161 ± 7	(50)	168 ± 8	(50)	173 ± 8	(50)	176 ± 8	(50)	180 ± 8
2%	(50)	156 ± 6	(50)	162 ± 6 *	(50)	167 ± 6	(50)	169 ± 6	(50)	173 ± 6 *

* Significantly different from coresponding control group.

Table 13 *(Continued)*

Summary of average body weight (g) and number of surviving rats (2-year carcinogenicity study)

Dammar resin	WEEK 21		WEEK 25		WEEK 29		WEEK 33		WEEK 37	
Male										
Control	(50)	371 ± 20	(50)	388 ± 21	(50)	400 ± 21	(50)	409 ± 22	(50)	419 ± 21
0.03%	(50)	396 ± 20 *	(50)	413 ± 21 *	(50)	426 ± 22 *	(50)	438 ± 22 *	(49)	449 ± 24*
0.5%	(50)	391 ± 18 *	(50)	406 ± 17 *	(50)	419 ± 19 *	(50)	429 ± 19 *	(50)	438 ± 19*
2%	(50)	360 ± 21 *	(50)	372 ± 20 *	(50)	378 ± 21 *	(50)	387 ± 21 *	(50)	393 ± 21*
Female										
Control	(49)	195 ± 8	(49)	201 ± 9	(49)	204 ± 9	(49)	205 ± 8	(49)	211 ± 9
0.03%	(50)	202 ± 8 *	(50)	210 ± 8 *	(50)	214 ± 9 *	(50)	216 ± 10 *	(50)	222 ± 10
0.5%	(50)	198 ± 9	(50)	204 ± 9	(50)	208 ± 9 *	(50)	212 ± 10 *	(50)	216 ± 10
2%	(50)	190 ± 6 *	(50)	195 ± 7 *	(50)	198 ± 7 *	(50)	201 ± 7	(50)	205 ± 8

* Significantly different from coresponding control group.

Table 13 *(Continued)*

Summary of average body weight (g) and number of surviving rats (2-year carcinogenicity study)

	WEEK 41			WEEK 45			WEEK 49			WEEK 53			WEEK 58		
Male															
Control	(50)	426 ± 23		(50)	434 ± 23		(50)	440 ± 24		(50)	447 ± 25		(50)	450 ± 26	
0.03%	(49)	458 ± 24	*	(49)	463 ± 23	*	(49)	470 ± 24	*	(49)	475 ± 26	*	(49)	480 ± 27	*
0.5%	(50)	447 ± 19	*	(49)	452 ± 20	*	(49)	458 ± 21	*	(49)	461 ± 23	*	(49)	466 ± 24	*
2%	(50)	400 ± 21	*	(50)	405 ± 22	*	(50)	410 ± 22	*	(50)	413 ± 23	*	(50)	416 ± 22	*
Female															
Control	(49)	215 ± 9		(49)	219 ± 10		(49)	222 ± 11		(49)	227 ± 11		(49)	232 ± 12	
0.03%	(50)	229 ± 11	*	(50)	233 ± 12	*	(50)	237 ± 12	*	(50)	241 ± 13	*	(49)	249 ± 19	*
0.5%	(50)	221 ± 10	*	(50)	226 ± 11	*	(50)	231 ± 11	*	(50)	236 ± 12	*	(50)	242 ± 14	*
2%	(50)	208 ± 8	*	(50)	211 ± 9	*	(50)	213 ± 9	*	(50)	217 ± 9	*	(49)	220 ± 10	*

* Significantly different from coresponding control group.

Table 13 *(Continued)*

Summary of average body weight (g) and number of surviving rats (2-year carcinogenicity study)

	WEEK 61		WEEK 65		WEEK 69		WEEK 73		WEEK 77	
Male										
Control	(50)	453 ± 27	(50)	457 ± 26	(50)	465 ± 28	(50)	468 ± 28	(50)	472 ± 29
0.03%	(49)	484 ± 28 *	(49)	486 ± 34 *	(48)	495 ± 30 *	(47)	504 ± 32 *	(47)	506 ± 31 *
0.5%	(49)	468 ± 25 *	(49)	470 ± 26	(49)	477 ± 28	(49)	482 ± 29 *	(49)	483 ± 28
2%	(50)	419 ± 23 *	(49)	421 ± 25 *	(47)	427 ± 22 *	(45)	431 ± 23 *	(45)	433 ± 24 *
Female										
Control	(49)	234 ± 13	(48)	237 ± 15	(48)	244 ± 18	(47)	251 ± 20	(46)	260 ± 21
0.03%	(48)	252 ± 19 *	(48)	255 ± 22 *	(46)	264 ± 22 *	(46)	273 ± 24 *	(46)	283 ± 25 *
0.5%	(50)	244 ± 16 *	(50)	247 ± 17 *	(50)	254 ± 18 *	(50)	262 ± 20 *	(50)	271 ± 22 *
2%	(49)	222 ± 10 *	(49)	223 ± 11 *	(49)	228 ± 12 *	(49)	233 ± 14 *	(49)	238 ± 15 *

* Significantly different from coresponding control group.